Novavax: Dead Cat Bounce
- Novavax, Inc. bounced on hype while the prospects from the business continued to dim with the demand for Covid vaccines.
- The small biotech has major doubts about the financial picture of the company considering the massive operating expense structure built up to produce Covid vaccines.
- Novavax stock remains a Sell due to like further dilution ahead and no logical path to profits.
- This idea was discussed in more depth with members of my private investing community, Out Fox The Street. Learn More »